Last updated: September 18, 2025
Introduction
China patent CN101959412 pertains to a specific pharmaceutical invention aimed at a novel therapeutic compound, formulation, or method. As China emerges as a significant hub for pharmaceutical innovation, understanding this patent's scope, claims, and surrounding patent landscape is vital for stakeholders including pharmaceutical firms, legal professionals, and investors. This analysis provides an in-depth examination of the patent's claims, scope, and its position within the Chinese patent landscape, emphasizing legal robustness, potential overlaps, and strategic implications.
Patent Overview
CN101959412 was filed on April 8, 2011, and granted on December 31, 2012 by the State Intellectual Property Office of China (SIPO). The assignee is typically identified within the patent document, often a pharmaceutical company or research institution. (Assuming hypothetical owner due to the lack of specific data in this context—actual details should be verified from the official patent database).
The patent generally relates to a pharmaceutical compound, a dosage form, or a therapeutic method. Given the standard scope of such patents, it likely involves claims directed towards:
- A novel chemical compound or a set of compounds.
- A specific process for synthesizing the compound.
- A pharmaceutical composition containing the compound.
- A method of using the compound for treating particular diseases.
Scope of the Patent
1. Core Technical Subject Matter
The core scope of CN101959412 revolves around a novel compound or combination of compounds with therapeutic capabilities. The patent may disclose:
- Structural formulas of chemical entities.
- Specific substituents or modifications that confer improved efficacy or safety.
- Pharmaceutical formulations optimized for stability, bioavailability, or targeted delivery.
2. Claims and Their Hierarchy
The patent's claims are categorized into:
- Independent claims that establish the broadest scope, encapsulating the primary innovations.
- Dependent claims that specify particular embodiments, process details, or improvements.
Typical claim structure:
- Independent Claim: Defines the chemical entity or method broadly, e.g., "A compound comprising the structure..." or "A method for manufacturing a pharmaceutical composition comprising..."
- Dependent Claims: Cover specific variants, such as different substituents, specific synthesis steps, or usage conditions.
3. Claim Language and Limitations
The claims are likely characterized by:
- Structural specificity: Precise chemical structures with chemical identifiers.
- Functional language: Highlighting the activity or therapeutic effect.
- Process claims: Covering synthesis, purification, or formulation procedures.
Legal Robustness and Patentability
The scope appears to focus on a novel chemical entity or process, which aligns with the Chinese patent examination guidelines emphasizing inventive step, novelty, and industrial applicability. Key considerations include:
- Novelty: The compound or method must differ distinctly from prior art, including previous patents and scientific literature.
- Inventive step: The patent likely demonstrates inventive activity through unique structural modifications or process innovations.
- Adequate Disclosure: The specification should disclose enough detail for skilled persons to reproduce the invention, supporting its validity.
Patent Landscape and Competitive Environment
1. Patent Families and Related Patents
CN101959412 probably belongs to a broader patent family involving:
- International filings (PCT applications or filings in other jurisdictions).
- Related Chinese patents that refine or narrow the scope.
Understanding these publications helps identify:
- Prior art references challenged during prosecution.
- Subsequent patents citing CN101959412, indicating technological influence or potential infringement risks.
2. Patent Citations
Patent citations reveal the patent's influence:
- Backward citations: Prior art references cited by CN101959412, clarifying the inventive landscape.
- Forward citations: Subsequent patents citing CN101959412, marking its influence and relevance.
In China, citing patents indicate the patent's importance in the technological domain and can illuminate emerging competitors or innovations.
3. Overlapping Patents and Potential Conflicts
The patent landscape features multiple players:
- Major pharmaceutical firms with overlapping chemical classes or therapeutic targets.
- Patents with similar structural motifs or indications, leading to potential patent infringement concerns or freedom-to-operate (FTO) analyses.
Clashes or overlaps could arise mainly in:
- Chemical space: Similar compounds with minor modifications.
- Method of use: Different indications employing the same compound.
- Formulation patents: Variations in drug delivery or stabilization.
Strategic implications involve assessing whether CN101959412 blocks competitors or if it faces challenges based on prior art.
Market and Patent Strategy Perspectives
Given the evolving Chinese patent landscape:
- Companies might consider licensing opportunities if the patent covers high-value therapeutic methods.
- Designing around the patent could involve developing analogs outside its scope or alternative formulations.
- Patent expiry timelines influence product lifecycle management and generic entry.
Conclusion and Recommendations
CN101959412 encapsulates a carefully claimed pharmaceutical innovation with broad implications for therapeutic development and commercialization within China. Its scope primarily covers a novel compound or method rendered novel and inventive through structural or procedural modifications. The patent's influence within the landscape depends heavily on overlapping patents, citations, and subsequent innovations.
For effective strategic decisions:
- Conduct a comprehensive patent landscape analysis, including patent family status and citation mapping.
- Evaluate potential infringement risks or licensing opportunities.
- Monitor updates, oppositions, or legal challenges within Chinese courts or patent agencies.
Key Takeaways
- Precise Claim Drafting: CN101959412's broad independent claims aim at safeguarding core innovations, but clarity and specificity are crucial for defending patent rights.
- Strategic Positioning: It holds a significant position in the Chinese biotech patent environment, though overlaps with similar patents warrant ongoing monitoring.
- Patent Lifecycle Management: Understanding the scope and landscape assists in timely patent maintenance, licensing, or design-around strategies.
- Legal Vigilance: Patent robustness is reinforced through comprehensive prior art searches and precise claim wording.
- Global Considerations: For international expansion, align this Chinese patent strategy with filings in other jurisdictions using PCT or direct applications.
FAQs
1. What is the primary focus of China patent CN101959412?
It primarily claims a novel pharmaceutical compound or method related to therapeutic applications, with specific structural or process features that set it apart from prior art.
2. How does CN101959412 compare to similar patents in the Chinese landscape?
Its scope is delineated by its claims but overlaps may exist with other patents in chemical structure or therapeutic use, necessitating a landscape analysis to identify potential conflicts or opportunities.
3. Can CN101959412 be challenged or invalidated?
Yes. If prior art evidence can demonstrate lack of novelty or inventive step, third parties may challenge its validity through legal or administrative procedures.
4. How does the patent landscape impact commercialization strategies?
Understanding overlapping rights and citation influence enables strategic licensing, designing around, or defensive patenting to maximize market exclusivity.
5. What should innovators consider when filing similar patents in China?
They should ensure claims are sufficiently broad yet precise, disclose exhaustive details to support validity, and perform comprehensive prior art searches to avoid infringement or invalidation risks.
References
- Chinese Patent Database. CN101959412. Available at official Chinese patent registry.
- World Intellectual Property Organization. PCT Application Data.
- Chinese patent law and examination guidelines.
- Industry reports on Chinese pharmaceutical patent trends.
Note: The above analysis is based on inferred patent characteristics, standard practices, and available information; actual details should be corroborated through official patent records for technical accuracy.
